Anisdahl K - Search Results

1

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW. Wiken TH, et al. Among authors: anisdahl k. Crohns Colitis 360. 2024 Feb 26;6(1):otae013. doi: 10.1093/crocol/otae013. eCollection 2024 Jan. Crohns Colitis 360. 2024. PMID: 38544907 Free PMC article.

2

Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study.

Anisdahl K, Lirhus SS, Medhus AW, Moum B, Melberg HO, Høivik ML. Anisdahl K, et al. Dig Liver Dis. 2024 Mar 2:S1590-8658(24)00262-7. doi: 10.1016/j.dld.2024.02.002. Online ahead of print. Dig Liver Dis. 2024. PMID: 38433021 Free article.

3

Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW. Wiken TH, et al. Among authors: anisdahl k. Scand J Gastroenterol. 2023 Jul-Dec;58(8):863-873. doi: 10.1080/00365521.2023.2176252. Epub 2023 Feb 17. Scand J Gastroenterol. 2023. PMID: 36799155

4

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ. Jørgensen KK, et al. Among authors: anisdahl k. Scand J Gastroenterol. 2023 Jul-Dec;58(8):874-882. doi: 10.1080/00365521.2023.2177884. Epub 2023 Feb 14. Scand J Gastroenterol. 2023. PMID: 36788656

5

Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.

Zhao M, Lirhus S, Lördal M, Langholz E, Knudsen T, Voutilainen M, Høivik ML, Moum B, Anisdahl K, Saebø B, Haiko P, Malmgren C, Coskun M, Melberg HO, Burisch J. Zhao M, et al. Among authors: anisdahl k. Aliment Pharmacol Ther. 2022 Sep;56(6):989-1006. doi: 10.1111/apt.17145. Epub 2022 Jul 28. Aliment Pharmacol Ther. 2022. PMID: 35902223

6

First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.

Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML. Anisdahl K, et al. Scand J Gastroenterol. 2021 Oct;56(10):1163-1168. doi: 10.1080/00365521.2021.1955147. Epub 2021 Jul 28. Scand J Gastroenterol. 2021. PMID: 34320885

7

Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study.

Lirhus SS, Høivik ML, Moum B, Anisdahl K, Melberg HO. Lirhus SS, et al. Among authors: anisdahl k. Clin Epidemiol. 2021 Apr 23;13:287-294. doi: 10.2147/CLEP.S303797. eCollection 2021. Clin Epidemiol. 2021. PMID: 33935519 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page